Rachna Shroff, MD
Hematology & Oncology · Tucson, AZNPI 1942425350
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $199,756 of the $249,799 with a category attached, or 80.0%. 36 manufacturers reported payments, led by AstraZeneca at 24.4% of the total. Reporting peaked in 2021 at $49,102 and has fallen 57.1% since, to $21,046 in 2025. Among hematology & oncology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 210 payments — averaging $1189.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$61K
- Astrazeneca UK Limited$40K
- Servier Pharmaceuticals LLC$21K
- Merck$20K
- Incyte Corporation$17K
- Agios Pharmaceuticals, Inc.$14K
- plus $76K from 30 others
Across 637 payments — averaging $4379.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$851K
- Eli Lilly$709K
- Bristol Myers Squibb$213K
- Exelixis Inc.$209K
- Novocure Inc.$175K
- Seagen Inc.$140K
- plus $493K from 13 others
What the payments were for
- Consulting fees$199,75680%
- Speaking & faculty fees$27,39811%
- Grants$1,8001%
- Travel & lodging$14,2716%
- Food & beverage$6,4643%
- Education$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 46 | $60,889 |
| Astrazeneca UK Limited | 11 | $40,406 |
| Servier Pharmaceuticals LLC | 9 | $20,691 |
| Merck | 28 | $20,391 |
| Incyte Corporation | 22 | $17,457 |
| Agios Pharmaceuticals, Inc. | 9 | $13,699 |
| Jazz Pharmaceuticals Inc. | 11 | $11,455 |
| Ipsen Biopharmaceuticals, Inc | 5 | $11,121 |
| Taiho Oncology, Inc. | 4 | $9,215 |
| Exelixis Inc. | 14 | $7,347 |
| Regeneron | 6 | $6,466 |
| Servier Affaires Medicales | 1 | $6,120 |
| Boehringer Ingelheim International GmbH | 3 | $5,988 |
| Boston Scientific | 9 | $3,435 |
| Daiichi Sankyo Inc. | 2 | $2,874 |
| Genentech USA, Inc. | 3 | $2,357 |
| Clovis Oncology, Inc. | 2 | $1,554 |
| Eisai Inc. | 1 | $1,360 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $1,068 |
| Boehringer Ingelheim Espana S.A. | 1 | $1,000 |
| Bayer | 1 | $900 |
| Halozyme Inc | 1 | $675 |
| AbbVie | 1 | $675 |
| Boehringer Ingelheim | 2 | $518 |
| EMD Serono, Inc. | 1 | $375 |
| Novocure Inc. | 1 | $368 |
| Merck Kgaa | 1 | $325 |
| Foundation Medicine, Inc. | 2 | $314 |
| Pfizer | 4 | $177 |
| Amgen | 1 | $143 |
| Gilead | 1 | $124 |
| Galvanize Therapeutics, Inc | 1 | $122 |
| Stryker | 1 | $59 |
| Array Biopharma Inc | 1 | $55 |
| Novartis | 1 | $49 |
| Lilly USA, LLC | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$58,848
- TIBSOVO$34,279
- ZANIDATAMAB$11,171
- ONIVYDE$11,121
- SAPHNELO$8,995
- TAZVERIK$7,641
- Cabometyx$5,182
- LENVIMA$4,512
- LYNPARZA$3,425
- INQOVI$3,300
- Lonsurf$2,640
- TECENTRIQ$2,200
- TheraSphere Y90 Glass Microspheres 10 GBq$1,860
- TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial)$1,575
- Lucitanib$1,500
- TRUSELTIQ$1,020
- Vitrakvi$900
- KEYTRUDA$289
- FOUNDATIONONE LIQUID CDX$216
- ZYNYZ$125
How this compares
$249,799 in reported general payments places this provider in the 95th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 29 | $71,799 |
| EliquisApixaban | 15 | $9,935 |
| Ondansetron OdtOndansetron | 55 | $1,449 |
| Prochlorperazine Maleate | 67 | $716 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 44 | $641 |
| Duloxetine Hcl | 26 | $506 |
| Oxycodone Hcl | 27 | $407 |
| Levothyroxine Sodium | 13 | $179 |
| Dexamethasone | 13 | $68 |
| Potassium Chloride | 11 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon | $675 | $71,79929 claims |
| PfizerEliquis | $177 | $9,93515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Tucson
- Christopher ChenTucson$370K
- Alison StopeckTucson$115K
- Jaspreet ChahalTucson$104K
- Basel ShouaTucson$98K
- Akshay AmaraneniTucson$93K
- Ahmed AbdelazizTucson$35K
- Michael BoxerTucson$30K
- Catherine AzarTucson$29K
- Ricklie JulianTucson$27K
- Sujith KalmadiChandler$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.